Summary
Stryker Corporation's second quarter 2015 results showed a notable increase in net earnings compared to the prior year, driven significantly by a reduction in recall charges. For the three months ended June 29, 2015, net sales grew 2.9% year-over-year to $2.43 billion, while net earnings surged by 206.3% to $392 million, or $1.03 per diluted share. This substantial earnings improvement was primarily attributed to a nearly 60% decrease in recall charges, particularly related to the Rejuvenate and ABG II hip stems. Excluding these recall charges and other adjustments, adjusted diluted EPS rose 11.1% to $1.20, indicating solid underlying operational performance. The company's balance sheet reflects a strong cash position, with cash and cash equivalents increasing significantly to $3.63 billion from $1.80 billion at the end of 2014. This was bolstered by strong operating cash flow and significant proceeds from the sale of marketable securities, which helped fund recall-related payments and other cash management activities. Despite a challenging international sales environment impacted by foreign currency exchange rates, Stryker demonstrated resilience, with constant currency sales growth across its segments, particularly in Neurotechnology and Spine, and MedSurg. The company continues to manage its capital effectively through share repurchases and dividend payments, signaling confidence in its financial health and future prospects.
Financial Highlights
50 data points| Revenue | $2.43B |
| Cost of Revenue | $827.00M |
| Gross Profit | $1.60B |
| R&D Expenses | $154.00M |
| SG&A Expenses | $861.00M |
| Operating Expenses | $1.18B |
| Operating Income | $429.00M |
| Net Income | $392.00M |
| EPS (Basic) | $1.04 |
| EPS (Diluted) | $1.03 |
| Shares Outstanding (Basic) | 377.00M |
| Shares Outstanding (Diluted) | 381.10M |
Key Highlights
- 1Net sales increased by 2.9% to $2.43 billion for the three months ended June 29, 2015, compared to $2.36 billion in the prior year.
- 2Net earnings dramatically increased by 206.3% to $392 million ($1.03 per diluted share) in Q2 2015, up from $128 million ($0.33 per diluted share) in Q2 2014.
- 3The substantial increase in net earnings was largely due to a significant reduction in recall charges, which decreased from $276 million in Q2 2014 to $112 million in Q2 2015.
- 4Adjusted diluted earnings per share (a non-GAAP measure) grew 11.1% to $1.20 in Q2 2015, indicating strong operational performance excluding specific charges.
- 5The company reported a strong cash position, with cash and cash equivalents increasing to $3.63 billion at June 30, 2015, up from $1.80 billion at December 31, 2014.
- 6International sales decreased by 9.9% as reported but showed growth of 4.1% on a constant currency basis, highlighting the impact of foreign exchange rates.
- 7The Orthopaedics segment saw modest reported sales growth of 0.6% ($1.03 billion), while MedSurg and Neurotechnology and Spine segments reported growth of 3.9% ($939 million) and 6.4% ($458 million) respectively.